Neeraj N. Iyer

Neeraj N. Iyer

Auto-generated profile, based on publicly available information

Neeraj N. Iyer

Novo Nordisk Inc., Plainsboro, NJ, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
MWMichael Wang
Michael Wang
KBKatharine Batt
Katharine Batt
CKCraig Kessler
Craig Kessler
ANAnne Neff
Anne Neff
NINeeraj N Iyer
Neeraj N Iyer
CKChristine L Kempton
Christine L Kempton
Internal consistency and item-total correlation of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adult people with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study Michael Wang,1 Katharine Batt,2 Craig Kessler,3 Anne Neff,4 Neeraj N Iyer,5 David L Cooper,5 Christine L Kempton6 1Hemophilia and Thrombosis Center, University of Colorado School of Medicine, Aurora, CO, 2Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, 3Department of Medicine and Pathology, Division of Hematology/Oncology, Georgetown University Hospital, Washington, DC, 4Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, 5Novo Nordisk Inc., Clinical, Medical, and Regulatory Affairs, Plainsboro, NJ, 6Departments of Pediatrics and Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA Background: The Pain, Functional Impairment, and Quality of Life study was an observational, cross-sectional assessment of the impact of pain on functional impairment and quality of life in adult people with hemophilia (PWH) of any severity in the USA who experience joint pain and/or bleeding.Objective: To assess internal consistency (IC) and item-total correlation (ITC) of assessment tools used in the Pain, Functional Impairment, and Quality of Life study.Methods: Participants completed 5 patient-reported outcome instruments (­EQ-5D-5L with visual analog scale, Brief Pain Inventory v2 Short Form [BPI], International Physical Activity Questionnaire [IPAQ], Short Form 36 Health Survey v2 [SF-36v2], and Hemophilia Activities List [HAL]) and underwent an optional physiotherapist-administered musculoskeletal exam (Hemophilia Joint Health Score v2.1) during routine visits. Reliability assessment included IC and ITC of each instrument.Results: A total of 381 adult PWH (median age, 34 years) were enrolled. Participants were predominantly white/non-Hispanic (69.2%); 75% had congenital hemophilia A, and 70.5% had severe hemophilia. A total of 310 subjects reported bleeding within the past 6 months (mean [SD] number of bleeds, 7.1 [13.00]). IC was generally high across the instruments employed (Cronbach’s alpha 0.79–0.98) with the exception of HAL use of transportation (0.58) and IPAQ total physical activity (0.51). ITC was high (Pearson’s product-moment correlation coefficient >0.20) for all items except the “vigorous intensity activities” item of IPAQ, which was applicable to less than one-third of participants. The ITCs were generally highest in domains/scores that measured the functional consequences of hemophilic arthropathy on mobility and pain.Conclusion: The demonstrated reliability (IC/ITC) of the patient-reported outcome instruments and Hemophilia Joint Health Score v2.1 support a role for these instruments in evaluating adult PWH in US clinical and research settings. Keywords: hemophilia, pain, functional impairment, quality of life, patient-reported outcome, joint health

1 November 2015 in Menopause
Verified
Journal Article
Closed access
DPDavid Portman
David Portman
LSLee Shulman
Lee Shulman
JYJason Yeaw
Jason Yeaw
SZSha Msc Zeng
Sha Msc Zeng
CUChioma Uzoigwe
Chioma Uzoigwe
NINeeraj N. Iyer
Neeraj N. Iyer
Objective: Estrogen therapy is considered to be the most effective treatment of vaginal atrophy (VA) symptoms. This retrospective study compares rates of pharmacy refill-based treatment persistence in women treated for VA with local estrogen therapy (LET) creams versus low-dose vaginally administered tablets. Methods: Study cohort included treatment-naive women aged 45 years or older within the IMS PharMetrics Plus claims database who filled one or more prescriptions for a LET cream or tablet between January 1, 2010 and September 30, 2012. Index LET was the first observed LET claim in pharmacy records. Persistence was defined as the number of consecutive days of treatment available of the index LET during the 12-month follow-up period. In adjusted analyses, we compared the risks of discontinuation of index therapy. Results: Of 30,197 women eligible for analysis, 12,187 (40.4%) initiated treatment with conjugated estrogens vaginal cream, 11,574 (38.3%) initiated treatment with estradiol vaginal cream, and 6,436 (21.3%) initiated treatment with 10-μg vaginal estradiol tablets (formulation introduced in 2010). Cohorts were comparable on age, geography, and baseline comorbidities. During the 12-month follow-up period, 86.2% to 89.4% of cream users discontinued LET after the first prescription compared with 57.8% of tablet users (P < 0.0001). A greater proportion of tablet initiators than cream users were fully (100%) persistent during the 12-month follow-up period. Mean treatment duration was 103.4 days for tablets versus 44.6 to 48.1 days for creams (P < 0.0001). After adjustment for baseline characteristics, tablet initiators had a lower risk of discontinuation compared with cream users (P < 0.0001). Conclusions: Low-dose LET tablets, compared with cream formulations, are associated with greater persistence in the treatment of VA.

20 March 2017 in European Journal of Haematology
Verified
Journal Article
Open access
PDF file
TBTyler W. Buckner
Tyler W. Buckner
MWMichelle Witkop
Michelle Witkop
CGChristine Guelcher
Christine Guelcher
MFMary Jane Frey
Mary Jane Frey
SHSusan Hunter
Susan Hunter
RSRobert Sidonio
Robert Sidonio
The Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B‐HERO‐S) initiative was launched in an effort to address specific gaps in the understanding of the psychosocial impact of mild‐moderate‐severe hemophilia B. The original Hemophilia Experiences, Results and Opportunities (HERO) qualitative study evaluated the needs of people with hemophilia A or B in multiple countries; however, a majority of participants had the more common moderate‐severe hemophilia A. The B‐HERO‐S study was designed in collaboration with the hemophilia community to evaluate the needs of adults with hemophilia B and caregivers of children with hemophilia B, including affected women and caregivers of girls with hemophilia. The report presented here describes participant demographics and comorbidities, as well as treatment regimens and access to treatment. Bleeding symptoms were reported by 27% of mothers of children with hemophilia B who participated. Women were more likely than men to self‐report arthritis and depression/anxiety as comorbidities associated with hemophilia B. More adults and children with hemophilia B were on routine treatment than on on‐demand treatment, and a high percentage of adults with moderate hemophilia B received routine treatment (86%). Many adults with hemophilia B (78%) and caregivers (69%) expressed concern about access to factor in the next 5 years, and of adults with hemophilia B, women more commonly experienced issues with access to factor in the past than did men (72% vs 44%). The findings of the B‐HERO‐S study reveal potential unmet needs of some patients with mild‐moderate hemophilia B, and the results may be leveraged to inform patient outreach by hemophilia treatment centers and education initiatives.

1 August 2020 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
JVJay Visaria
Jay Visaria
NINeeraj N Iyer
Neeraj N Iyer
ARAmit D Raval
Amit D Raval
SKSheldon X Kong
Sheldon X Kong
THTodd Hobbs
Todd Hobbs
VWVincent J Willey
Vincent J Willey
Objective: The objective of this study was to estimate the incremental long-term costs associated with T2DM attributable to vascular diseases. Research Design and Methods: This retrospective cohort study identified newly diagnosed (incident) T2DM patients in 2007 (baseline to 01/01/2006) using the HealthCore Integrated Research Database, a repository of nationally representative claims data. Incident T2DM patients were 1:1 exact matched on age, gender and other factors of interest to non-DM patients, and followed until the earlier of 8 follow-up years or death. Patients with documented vascular disease diagnosis were identified during the study period. All-cause and T2DM/vascular disease-related annual healthcare costs were examined for each follow-up year. Results: The study included 13,883 individuals with T2DM and matched non-DM controls. Among individuals with T2DM, 11,792 (85%) had vascular disease versus 9251 (66.6%) non-T2DM between 01/01/2006 and 12/31/2015. Among T2DM patients, mean all-cause annual costs were greater than in non-T2DM patients ($13,806 vs $7,243, baseline, $21,745 vs $8,524, post-index year 1, $12,756-$14,793 vs $8,349-$9,940 years 2– 8, p< 0.001), respectively. A similar trend was observed for T2DM/vascular disease-related costs (p< 0. 001). T2DM/vascular disease-related costs were largest during post-index year 1, accounting for the majority of all-cause cost difference between T2DM patients and matched non-DM controls. Incident T2DM individuals without vascular disease at any time had significantly lower costs compared to non-DM controls (p< 0. 001) between years 2– 8 of follow-up. Conclusion: Vascular disease increased the cost burden for individuals with T2DM. The cost impact of diabetes and vascular disease was highest in the year after diagnosis, and persisted for at least seven additional years, while the cost of T2DM patients without vascular disease trended lower than for matched non-DM patients. These data highlight potential costs that could be offset by earlier and more effective detection and management of T2DM aimed at reducing vascular disease burden.

2 March 2018 in European Journal of Haematology
Verified
Journal Article
Open access
PDF file
CKChristine L. Kempton
Christine L. Kempton
TBTyler W. Buckner
Tyler W. Buckner
MFMoshe Fridman
Moshe Fridman
NINeeraj N. Iyer
Neeraj N. Iyer
DCDavid L. Cooper
David L. Cooper
Introduction: Levels of pain and dysfunction appear to differ among people with hemophilia despite similar levels of joint disease.Objective: To determine patient characteristics that influence pain and function independent of joint status.Methods: US adults with hemophilia completed a survey that included information on clinical characteristics, demographics, and patient‐reported outcome instruments assessing pain (Brief Pain Inventory v2 Short Form [BPI]), functional impairment (Hemophilia Activities List [HAL]), and health status (EQ‐5D‐5L). Additionally, physiotherapists optionally completed a clinical joint evaluation (Hemophilia Joint Health Score [HJHS]). Associations were examined using simple and multiple regression models.Results: Of 381 adults enrolled, 240 had complete HJHS scores (median age, 32 years). After controlling for HJHS and opiate use, anxiety/anxiolytic use was significantly associated with worse pain severity and interference scores. After controlling for HJHS, the most significant predictors of functional impairment were older age, unemployment, more severe hemophilia, and greater pain. EQ‐5D‐5L pain/discomfort was associated with worse outcomes on most HAL scores.Conclusion: Unemployment, anxiety, and depression were each associated with both greater pain and functional disability after controlling for joint status. Continued attention to pain and psychosocial issues will be important in improving clinical care and research efforts in the hemophilia population.

2 September 2021 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
AMArshiya Mariam
Arshiya Mariam
GMGalen Miller‐Atkins
Galen Miller‐Atkins
KPKevin Pantalone
Kevin Pantalone
NINeeraj Iyer
Neeraj Iyer
AMAnita D. Misra‐Hebert
Anita D. Misra‐Hebert
DRDaniel Rotroff
Daniel Rotroff
Aims: To determine the health outcomes associated with weight loss in individuals with obesity, and to better understand the relationship between disease burden (disease burden; ie, prior comorbidities, healthcare utilization) and weight loss in individuals with obesity by analysing electronic health records (EHRs). Materials and Methods: We conducted a case‐control study using deidentified EHR‐derived information from 204 921 patients seen at the Cleveland Clinic between 2000 and 2018. Patients were aged ≥20 years with body mass index ≥30 kg/m 2 and had ≥7 weight measurements, over ≥3 years. Thirty outcomes were investigated, including chronic and acute diseases, as well as psychological and metabolic disorders. Weight change was investigated 3, 5 and 10 years prior to an event. Results: Weight loss was associated with reduced incidence of many outcomes (eg, type 2 diabetes, nonalcoholic steatohepatitis/nonalcoholic fatty liver disease, obstructive sleep apnoea, hypertension; P < 0.05). Weight loss >10% was associated with increased incidence of certain outcomes including stroke and substance abuse. However, many outcomes that increased with weight loss were attenuated by disease burden adjustments. Conclusions: This study provides the most comprehensive real‐world evaluation of the health impacts of weight change to date. After comorbidity burden and healthcare utilization adjustments, weight loss was associated with an overall reduction in risk of many adverse outcomes.